MBrace Therapeutics Appoints Steve Alley as Chief Scientific Officer

– Dr. Alley brings 20 years of discovery and drug development experience from the clinical development programs and robust commercial portfolio of antibody-drug conjugates at Seagen, Inc. –

SAN DIEGO (March 5, 2024) – MBrace™ Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of patients with cancer by developing novel antibody-drug conjugates (ADCs), today announced the appointment of Steve Alley, Ph.D., as chief scientific officer. Dr. Alley joins MBrace with over 20 years of experience at Seagen, a world-leader in ADCs that was acquired by Pfizer in 2023.

“We are thrilled to welcome Dr. Alley to the MBrace team. Dr. Alley has exceptional expertise in ADC development, and his vision will undoubtedly help propel the progress for our discovery and clinical programs,” said Isan Chen, M.D., president and chief executive officer at MBrace Therapeutics. “Dr. Alley’s proven track record for strategically prioritizing and advancing the development candidates, the clinical and commercial activities in an organization that experienced rapid growth during his tenure aligns with our commitment to innovation and will be pivotal to the development of our pipeline and investigational ADC, MBRC-101, currently in Phase 1 studies.”

Read full article on mbracetrx.com

Share this page on social

Ready to get started? See what Samba can do for you.